Tesofensine

Base Information

• Chemical Name: Tesofensine
• CAS No.: 195875-84-4
• Deprecated CAS: 402856-42-2
• Molecular Formula: C17H23Cl2NO
• Molecular Weight: 328.28
• UNII: BLH9UKX9V1
• ChEMBL ID: CHEMBL3989690
• DSSTox Substance ID: DTXSID70905114
• Metabolomics Workbench ID: 149647
• NCI Thesaurus Code: C66589
• Pharos Ligand ID: PNWZ3GFHUVGC
• Wikidata: Q7705544
• Wikipedia: Tesofensine
• Mol file: 195875-84-4.mol

Synonyms:(1R-(2-endo,3-exo))-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo(3,2,1)octane-2-hydroxy-1,2,3-propanetricarboxylate;Tesofensine

Chemical Property of Tesofensine

Chemical Property:

• Boiling Point: 396.6 °C at 760 mmHg
• PKA: 10.46±0.60(Predicted)
• Flash Point: 193.7 °C
• PSA: 12.47000
• Density: 1.161 g/cm³
• LogP: 4.53410
• XLogP3: 4.5
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 4
• Exact Mass: 327.1156697
• Heavy Atom Count: 21
• Complexity: 354

Purity/Quality:

98% ^*data from raw suppliers

Tesofensine ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCOCC1C2CCC(N2C)CC1C3=CC(=C(C=C3)Cl)Cl
• Isomeric SMILES: CCOC[C@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl
• Recent ClinicalTrials: A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
• Recent EU Clinical Trials: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose finding, Multi-center, 36-week Safety and Efficacy Study with Open-label Extension Period of Tesomet in Subjects with Hypothalamic Obesity
• Uses: Tesofensine, is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is currently in clinical development for the treatment of obesity.